Beranda › Kanker Lambung › Pennsylvania › Pittsburgh
Uji klinis Kanker Lambung di Pittsburgh, PA
14 studi untuk Kanker Lambung mencari peserta di lokasi sekitar Pittsburgh (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Distance-Based Exercise to Preserve Function and Prevent Disability
Menerima peserta
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Menerima pesertaFase 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Menerima pesertaFase 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Menerima pesertaFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Menerima pesertaFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Menerima pesertaFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Menerima pesertaFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Menerima pesertaFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Menerima pesertaFase 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Menerima pesertaFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Menerima pesertaFase 1
- AHN West Penn Hospital, Pittsburgh
Uji klinis Kanker Lambung di kota lain
- Houston, TX42 studi
- Boston, MA32 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Baldwin Park, CA22 studi
- Los Angeles, CA22 studi
- Arlington, VA20 studi
- Dallas, TX19 studi
- San Antonio, TX19 studi
- St. Louis, MO18 studi
- Grand Rapids, MI18 studi
- Washington, DC16 studi
Studi lain di Pittsburgh
- Kanker Paru Non-Sel Kecil48 studi
- Kanker (semua jenis)41 studi
- Kanker Payudara39 studi
- Kanker Kolorektal32 studi
- Kanker Metastatik31 studi
- Melanoma31 studi
- Kanker Ovarium30 studi
- Kanker Endometrium23 studi
- Kanker Prostat23 studi
- Kanker Paru23 studi
- Karsinoma Sel Skuamosa Kepala dan Leher22 studi
- Stroke22 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.